Profile cover photo
Profile photo
Capstone Therapeutics Corp.
8 followers -
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy.
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy.

8 followers
About
Capstone Therapeutics Corp.'s posts

Post has attachment

Post has attachment
Metabolic syndrome is defined as a group of risk factors such as high levels of LDL cholesterol and triglycerides, increased blood pressure, and abdominal obesity. When these components are grouped together the risk of heart disease grows significantly. http://bit.ly/1D2asNQ

Post has attachment
Our Apo E mimetics restore natural pathways missing in patients suffering from acute coronary syndrome. http://bit.ly/1Qp9RLX

Our proven Apo-E class of lipid lowering drugs aim to treat hyperlipidemic indications such as atherosclerosis.

Post has attachment

Post has attachment
Modification and derivatization of LipimetiX's AEM-28 has resulted in the Chimeric Apo E Mimetic Peptide (CHAMP) technology, creating a suite of Apo E mimetic peptides with enhanced efficacy and diverse functionality. http://bit.ly/1Xz4Dhb

Post has attachment
Did you know atherosclerosis can lead to serious health problems, including heart attack, stroke or even death? http://1.usa.gov/1XHEmf3

Post has attachment
Through our investment in LipimetiX, Capstone Therapeutics is able to focus on the development and commercialization of Apo E mimetic peptide AEM-28 and analogs to help patients with under-served medical conditions. http://bit.ly/1S4zeji

Post has attachment
LipimetiX's base peptide, AEM-28, has demonstrated remarkable VLDL cholesterol and triglyceride reductions in Phase 1 and Phase 2 human clinical trials. http://bit.ly/1R5mNpi

Post has attachment
Click to learn more about Capstone Therapeutics and our work developing a pipeline of novel peptides and other molecules to help patients with underserved medical conditions such as acute pancreatitis and Homozygous Familial Hypercholesterolemia (HoFH): http://bit.ly/1XinjBV
Wait while more posts are being loaded